Beta Drugs (NSE:BETA) LT-Debt-to-Total-Asset: 0.27 (As of Mar. 2026)


NSE:BETA Beta Drugs Ltd NSE:BETA
88 GF Score
Price ₹2,153.40
GF Value ₹1,971.70
Valuation Fairly Valued
! 6 Warning Signs
View Full Analysis

What is Beta Drugs LT-Debt-to-Total-Asset?

Beta Drugs NSE:BETA +3.01% 88 LT-Debt-to-Total-Asset is 0.27 as of Mar. 2026. GuruFocus rates NSE:BETA with a GF Score™ of 88/100 and a GF Value™ of ₹1,971.70 (Fairly Valued). The stock has 6 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Beta Drugs's long-term debt to total assests ratio for the quarter that ended in Mar. 2026 was 0.27.

Beta Drugs's long-term debt to total assets ratio increased from Dec. 2024 (0.00) to Mar. 2026 (0.27). It may suggest that Beta Drugs is progressively becoming more dependent on debt to grow their business.

Beta Drugs  (NSE:BETA) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Beta Drugs LT-Debt-to-Total-Asset Related Terms

Beta Drugs LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Beta Drugs's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Beta Drugs LT-Debt-to-Total-Asset Chart

Beta Drugs Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.08 0.04 0.02 0.29 0.27

Beta Drugs Quarterly Data
Mar17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Dec24 Mar25 Sep25 Dec25 Mar26
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.29 0.28 0.00 0.27
NSE:BETA
88GF Score
Beta Drugs Ltd NSE:BETA
LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Beta Drugs LT-Debt-to-Total-Asset Calculation

Beta Drugs's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (A: Mar. 2026 )=Long-Term Debt & Capital Lease Obligation (A: Mar. 2026 )/Total Assets (A: Mar. 2026 )
=1333.247/4957.996
=0.27

Beta Drugs's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (Q: Mar. 2026 )=Long-Term Debt & Capital Lease Obligation (Q: Mar. 2026 )/Total Assets (Q: Mar. 2026 )
=1333.247/4957.996
=0.27

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 0.27 mean?
Beta Drugs (NSE:BETA) has a LT-Debt-to-Total-Asset of 0.27 as of Mar. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Beta Drugs and its competitors.
Is Beta Drugs' LT-Debt-to-Total-Asset too high?
Beta Drugs' current LT-Debt-to-Total-Asset is 0.27. Overall, Beta Drugs has a GF Score™ of 88/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Beta Drugs' LT-Debt-to-Total-Asset compare to ZTS and UTHR?
Beta Drugs' LT-Debt-to-Total-Asset of 0.27 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Drug Manufacturers company?
A good LT-Debt-to-Total-Asset depends on the Drug Manufacturers industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Beta Drugs and its competitors. Beta Drugs's current LT-Debt-to-Total-Asset is 0.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beta Drugs stock overvalued right now?
Based on GuruFocus' analysis, Beta Drugs (NSE:BETA) is currently considered Fairly Valued. The stock's GF Value™ is ₹1,971.70, compared to a current price of ₹2,153.40 — trading 9.2% above its estimated fair value. The current LT-Debt-to-Total-Asset is 0.27. Beta Drugs' overall GF Score™ is 88/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Beta Drugs (NSE:BETA), the current LT-Debt-to-Total-Asset is 0.27 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Beta Drugs (NSE:BETA) Overvalued in 2026?

Based on GuruFocus' analysis, Beta Drugs stock appears to be overvalued. The current stock price of ₹2,153.40 is trading 9.2% above its estimated GF Value™ of ₹1,971.70. GuruFocus considers Beta Drugs to be Fairly Valued.

Key valuation signals for NSE:BETA:

  • LT-Debt-to-Total-Asset: 0.27
  • GF Value™: ₹1,971.70 vs. price of ₹2,153.40 (9.2% above fair value)
  • GF Score™: 88/100 with 6 warning signs

No single metric tells the full story. See the NSE:BETA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Beta Drugs Business Description

Address SCO-184, First Floor, Sector-5, Panchkula, HR, IND, 134114
Beta Drugs Ltd operates in the pharmaceutical industry. The company manufactures and sells Oncology products in the form of tablets, capsules, oral formulations, and injections. It sells the products in India and also exports them to other countries, of which key revenue is derived from the sales made in India.
88GF Score

Get the complete analysis for NSE:BETA

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹2,153.40
Price
₹1,971.70
GF Value